Advertisement

Topics

Latest "Fondation IPSEN" News Stories

06:36 EST 23rd February 2019 | BioPortfolio

Here are the most relevant search results for "Fondation IPSEN" found in our extensive news archives from over 250 global news sources.

More Information about Fondation IPSEN on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fondation IPSEN for you to read. Along with our medical data and news we also list Fondation IPSEN Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fondation IPSEN Companies for you to search.

Showing "Fondation IPSEN" News Articles 1–25 of 136

Extremely Relevant

CohBar Founder Dr. Nir Barzilai Awarded the 2018 Fondation IPSEN Longevity Prize

MENLO PARK, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that company co-founder Dr. Nir Barzilai has been awarded the Fondation IPSEN Longevity Prize during the 22nd Geriatric Society of America meeting, which was held on November 17 ...


Raising Awareness about Early Onset Dementia: “Don’t Leave me now”, Written by Brian Daniels

Fondation IPSEN invites you to attend to a play about caring for people with early onset Alzheimer’s or cerebral dementia A free event open to everyoneNovember 21st, 4 pm The Fondation IPSEN is delighted to invite you to a theatre performance about familial upheavals when a family member is affected by Alzheimer’s disease ...

Relevant

L'innovateur Walid Al Banna Remporte la Saison 10 de Stars of Science de la Fondation du Qatar

DOHA, Qatar, November 24, 2018 /PRNewswire/ -- L'émission phare de la Fondation du Qatar appelle les talents scientifiques arabes à postuler pour participer à la Read more...


Ipsen to present new data from its oncology portfolio at the 2018 European Society for Medical ...

For further information :IpsenMediaIan Weatherhead, +44 (0) 1753 627733Vice President, Corporate External Communicationsian.weatherhead@ipsen.comorFanny Allaire, +33 (0) 1 58 33 58 96Director, Corporate External CommunicationsFanny.allaire@ipsen.comorFinancial CommunityEugenia Litz, +44 (0) 1753 627721Vice President, Investor Relationseugenia.litz@ipsen.c...

Ipsen appoints new general manager for the UK & Ireland

The French pharma company appointed a new general manager for its UK and Ireland office, Asad Mohsin Ali, who brings two decades of commercial experience and a bold vision for Ipsen’s global footprint expansion. Ali joins Ipsen from his former ro...

Ipsen seeks candidates as it looks to spend over €1bn on pipeline growth

Ipsen is actively scouting candidates to boost its oncology, rare disease and neuroscience portfolio, said chief business officer Ivana Magovčević-Liebisch. The...Read More... The post Ipsen seeks candidates as it looks to spend over €1bn on pipeline growth appeared first on Pharmaceutical Technology.

Exelixis and Ipsen start COSMIC-312 trial for advanced HCC

Exelixis and Ipsen have begun the Phase III COSMIC-312 trial of cabozantinib (cabometyx) in combination with atezolizumab (tecentriq) against sorafenib...Read More... The post Exelixis and Ipsen start COSMIC-312 trial for advanced HCC appeared first on Drug Development Technology.

With New HQ, Ipsen to Rapidly Expand North American Presence

With a patient-centric focus, Ipsen Biopharmaceuticals is on a mission to improve patients’ lives, leveraging its global reach and placing a strategic focus on external innovation.

First Patient Dosed in Ipsen and 3BP's Phase I/II Cancer Study

NewsIPN01087 is a compound that targets cancer cells in patients with advanced solid tumors which express the Neurotensin Receptor Subtype 1.

Exelixis, Ipsen's liver cancer drug approved in EU

The European Commission has approved Exelixis and Ipsen Pharma's Cabometyx, or cabozantinib, as a monotherapy in adult patien -More- 

STAT Plus: French pharma company Ipsen set to open Boston incubator this spring

The French pharmaceutical giant Ipsen is opening its new accelerator in Boston in April — and it’s already signed its first tenant.

NICE reverses decision, recommends Ipsen's kidney cancer drug for NHS use

The National Institute for Health and Care Excellence recommended Ipsen's Cabometyx, or cabozantinib, for National Health Ser -More- 

EMA committee recommends approval of Ipsen's Cabometyx tablets for previously treated HCC

Exelixis, Inc has announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency

Overseas Regulator Helps Ipsen Score A First In Australia

Ipsen’s tyrosine kinase inhibitor, Cabometyx, is the first product to be registered under a new Australian procedure that aims to...   

French pharma group Ipsen closes in on its next drug deals

French drugmaker Ipsen plans to bring in multiple new medicines through a series of transactions and sees the recent price drop of biotech stocks as increasing deal opportunities, its chief executive said on Wednesday.

NICE u-turn recommends Ipsen’s Cabometyx for kidney cancer

NHS funding for Ipsen’s Cabometyx is now being recommended by the National Institute for Health and Care Excellence to treat kidney cancer.

Ipsen’s Cabometyx wins EU nod for liver cancer

Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.

Ipsen strengthens oncology R&D team with two experts

French pharma company Ipsen has hired two R&D leaders to boost the company’s oncology arm. The new recruits – Dr Yan Moore and Dr Alexander (Sandy) McEwan – will bring their expertise to the company, which specialises in oncology, neuroscience...

Ipsen S.A. Strategy, SWOT and Corporate Finance Report [Report Updated: 28072018] Prices from USD $175

Ipsen S.A. Strategy, SWOT and Corporate Finance ReportSummaryIpsen S.A. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.Key HighlightsIpsen S.A. Ipsen or 'the company' is a global biop...

Ipsen warns over medicine supplies amid Brexit uncertainty

France’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma industry and patients’ access to medicines. As Theresa May attempts to drum up support for her Brexit deal, the French pharma said it was taking s...

IPSEN: Disclosure of Transactions in Own Shares between 17/09/2018 and 21/09/2018

Regulatory News: IPSEN: Aggregated presentation by day and market Issuer name Issuer identification code Transactiondate Identification code of thefinancial instrument Daily total volume (innumber...

IPSEN: Disclosure of Transactions in Own Shares between 27/08/2018 and 31/08/2018

Regulatory News: IPSEN: Aggregated presentation by day and market Issuer name Issuer identification code Transactiondate Identification code of thefinancial instrument Daily total volume (innumber...

IPSEN: Disclosure of Transactions in Own Shares between 10/09/2018 and 14/09/2018

Regulatory News: IPSEN: Aggregated presentation by day and market Issuer name Issuer identification code Transactiondate Identification code of thefinancial instrument Daily total volume (innumber...

EU approves Ipsen's Cabometyx in second line liver cancer

The European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar. The commission granted a marketing authorisation for Cabometyx (cabozantinib) as second line monotherapy for hepatocellular...

Cash-Rich Ipsen Opens Up Checkbook For 2019

2019 looks set to be a transformative year for Ipsen, with a pivotal clinical trial readout expected for combination Cabometyx...   


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks